EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Anti-SARS-CoV-2 total immunoglobulin and neutralising antibody responses in healthy blood donors throughout the COVID-19 pandemic: a longitudinal observational study

Yukino Gütlin, Diana Albertos Torres, Alexander Gensch, Ann-Kathrin Schlotterbeck, Laurent Stöger, Stefanie Heller, Laura Infanti, Güliz Tuba Barut, Volker Thiel, Karoline Leuzinger, Hans H Hirsch, Andreas Buser und 1 weitere

Swiss Medical Weekly · 2024

DOI: 10.57187/s.3408 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Swiss Medical Weekly, 2024. Verfasst von Yukino Gütlin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Antibodies, Viral, Blood Donors, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Quantifying antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and neutralising antibodies may help to understand protection at the individual and population levels. Determination of neutralising antibodies using classical virus neutralisation tests (VNT) is considered the gold standard, but they are costly and time-intensive. Enzyme-linked immunosorbent assay (ELISA)-based surrogate VNTs (sVNT) or anti-SARS-CoV-2 spike protein receptor binding domain immunoglobulins (anti-S-RBD Ig) may be suitable alternatives to VNTs. We aimed to (a) explore the correlations between anti-S-RBD Ig, VNT, and sVNT measurements and (b) describe humoral immunity against SARS-CoV-2 after vaccination, natural infection, and vaccine breakthrough infection in healthy blood donors. METHODS: We measured total anti-SARS-CoV-2 Ig in 5714 serum samples from 2748 healthy individuals visiting the Swiss Red Cross Blood Donation Centre in Basel from 03/2020 to 04/2022. We used the Elecsys® Anti-SARS-CoV-2 immunoassay (Roche) against the N- and S-receptor binding domain (RBD) proteins. In a subset of 548 samples from 123 donors, we conducted sVNTs against the Wuhan wild-type SARS-CoV-2 (SARS-CoV-2 Neutralizing Antibodies Detection Kit; Adipogen™). In 100 samples from 40 donors, we correlated sVNT and VNTs against the wild-type (D614G WU1) virus. Surveys were sent to the blood donors to collect data on their SARS-CoV-2 infection and vaccination status. Using this data, donors were categorised as “vaccination only”, “infection before vaccination”, “post-vaccine breakthrough infection”, and “natural infection only”. RESULTS: Our longitudinal observation study cohort consisted of 50.7% males with a median age of 31 years (range 18–75 y). Anti-SARS-CoV-2 N protein positivity rates per month indicate 57.1% (88/154) of the cohort was infected up to 04/2022. No differences in seropositivity were found between sexes, age groups, blood types (AB0 or RhD), and cytomegalovirus serostatus. We observed a high correlation between anti-S-RBD Ig and inhibition percentage (Spearman’s ρ = 0.92, Kendall’s τ = 0.77, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, NeutralizingAntibodies, ViralBlood DonorsCOVID-19AdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultEnzyme-Linked Immunosorbent AssayLongitudinal StudiesNeutralization TestsSARS-CoV-2Spike Glycoprotein, CoronavirusSwitzerland

Substanzen

Antibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
  • Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Regional Blood Transfusion Service Swiss Red Cross, Basel, Switzerland.
  • Institute of Virology and Immunology, Bern and Mittelhäusern, Switzerland.
  • Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Multidisciplinary Center for Infectious Diseases, University of Bern, Bern, Switzerland.

Zitieren

APA

Gütlin, Y., Albertos Torres, D., Gensch, A., Schlotterbeck, A. K., Stöger, L., Heller, S., Infanti, L., Barut, G. T., Thiel, V., Leuzinger, K., Hirsch, H. H., Buser, A., & Egli, A. (2024). Anti-SARS-CoV-2 total immunoglobulin and neutralising antibody responses in healthy blood donors throughout the COVID-19 pandemic: a longitudinal observational study. Swiss Medical Weekly. https://doi.org/10.57187/s.3408

Vancouver

Gütlin Y, Albertos Torres D, Gensch A, Schlotterbeck AK, Stöger L, Heller S, et al. Anti-SARS-CoV-2 total immunoglobulin and neutralising antibody responses in healthy blood donors throughout the COVID-19 pandemic: a longitudinal observational study. Swiss Medical Weekly. 2024. doi:10.57187/s.3408

BibTeX
@article{Gtlin2024,
  author = {Gütlin, Yukino and Albertos Torres, Diana and Gensch, Alexander and Schlotterbeck, Ann-Kathrin and Stöger, Laurent and Heller, Stefanie and Infanti, Laura and Barut, Güliz Tuba and Thiel, Volker and Leuzinger, Karoline and Hirsch, Hans H and Buser, Andreas and Egli, Adrian},
  title = {Anti-SARS-CoV-2 total immunoglobulin and neutralising antibody responses in healthy blood donors throughout the COVID-19 pandemic: a longitudinal observational study},
  journal = {Swiss Medical Weekly},
  year = {2024},
  doi = {10.57187/s.3408}
}
Kostenlos starten →